---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-000820"
form_type: "8-K"
ticker: "USNA"
cik: "0000896264"
company_name: "USANA HEALTH SCIENCES INC"
filed_at: "2022-07-06T23:59:59+00:00"
generated_at: "2026-06-24T21:09:06.346239+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# USANA preliminary Q2 net sales ~$265M (down 21% YoY); cuts FY2022 guidance sharply

## Summary
- Preliminary Q2 net sales ~$265M vs $337M a year ago; EPS ~$1.05 vs $1.87.
- FY2022 guidance cut: net sales now $1.015-1.065B (prev. $1.1-1.2B); EPS $3.85-4.45 (prev. $5.00-5.70).
- COVID lockdowns in China and regional sales program disruption drove weaker Q2 results.
- CEO Kevin Guest cites lower program participation and inflationary pressures; final Q2 results due July 26.

## SEC filing metadata
- accession: 0001157523-22-000820
- form_type: 8-K
- ticker: USNA
- cik: 0000896264
- company_name: USANA HEALTH SCIENCES INC
- filed_at: 2022-07-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/896264/000115752322000820/0001157523-22-000820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/896264/000115752322000820/a52772859.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-000820
- JSON: https://secwatch.observer/filing/0001157523-22-000820.json
- Plain text: https://secwatch.observer/filing/0001157523-22-000820.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.